{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T21:40:06Z","timestamp":1720388406985},"reference-count":54,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1136\/bmjgast-2018-000207","type":"journal-article","created":{"date-parts":[[2018,6,30]],"date-time":"2018-06-30T06:35:11Z","timestamp":1530340511000},"page":"e000207","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world effectiveness of sofosbuvir plus ribavirin for chronic hepatitis C genotype 2 in Asia: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"5","author":[{"given":"Bin","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanpu","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee Hui","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiichi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biyao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D","family":"Stave","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangsuo","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongfang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiro","family":"Furusyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramsey C","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindie H","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"key":"2018062923350626000_5.1.e000207.1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Polaris Observatory HCV Collaborators","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2018062923350626000_5.1.e000207.2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2468-1253(16)30080-2","article-title":"Management of hepatitis C virus infection in the Asia-Pacific region: an update","volume":"2","author":"Lim","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2018062923350626000_5.1.e000207.3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v22.i34.7824"},{"key":"2018062923350626000_5.1.e000207.4","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12601"},{"key":"2018062923350626000_5.1.e000207.5","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/jvh.12499","article-title":"A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus","volume":"23","author":"Ahn","year":"2016","journal-title":"J Viral Hepat"},{"key":"2018062923350626000_5.1.e000207.6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/TCRM.S134818","article-title":"Efficacy and safety outcomes of sofosbuvir-based treatment regimens for hepatitis C virus-infected patients with or without cirrhosis from phase III clinical trials","volume":"13","author":"Yang","year":"2017","journal-title":"Ther Clin Risk Manag"},{"key":"2018062923350626000_5.1.e000207.7","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12312"},{"key":"2018062923350626000_5.1.e000207.8","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the screening care and treatment of persons with chronic hepatitis C infection: updated version. Geneva, 2016."},{"key":"2018062923350626000_5.1.e000207.9","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12072-016-9717-6","article-title":"APASL consensus statements and recommendation on treatment of hepatitis C","volume":"10","author":"Omata","year":"2016","journal-title":"Hepatol Int"},{"key":"2018062923350626000_5.1.e000207.10","first-page":"154","article-title":"Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: a concise review","volume":"15","author":"Burgess","year":"2016","journal-title":"Ann Hepatol"},{"key":"2018062923350626000_5.1.e000207.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1316145"},{"key":"2018062923350626000_5.1.e000207.12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3904\/kjim.2015.30.4.423","article-title":"A 2015 roadmap for the management of hepatitis C virus infections in Asia","volume":"30","author":"Lim","year":"2015","journal-title":"Korean J Intern Med"},{"key":"2018062923350626000_5.1.e000207.13","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13300"},{"key":"2018062923350626000_5.1.e000207.14","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/liv.13206","article-title":"Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials","volume":"37","author":"Tacke","year":"2017","journal-title":"Liver Int"},{"key":"2018062923350626000_5.1.e000207.15","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-311609"},{"key":"2018062923350626000_5.1.e000207.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512610"},{"key":"2018062923350626000_5.1.e000207.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.039"},{"key":"2018062923350626000_5.1.e000207.18","unstructured":"U.S. National Library of Medicine. Asia [database on the Internet]. https:\/\/www.ncbi.nlm.nih.gov\/mesh\/68001208 (cited 30 Jun 2017)."},{"key":"2018062923350626000_5.1.e000207.19"},{"key":"2018062923350626000_5.1.e000207.20","unstructured":"Wells GA SB , O\u2019Connell D , Peterson J , et al . The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"2018062923350626000_5.1.e000207.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2015.09.002"},{"key":"2018062923350626000_5.1.e000207.22","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.12"},{"key":"2018062923350626000_5.1.e000207.23","doi-asserted-by":"publisher","DOI":"10.1186\/2049-3258-72-39"},{"key":"2018062923350626000_5.1.e000207.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"2018062923350626000_5.1.e000207.25","unstructured":"Michael Borenstein LVH , Higgins JPT , Rothstein HR . Chapter 20: meta-regression. In: Introduction to meta-analysis: John Wiley & Sons, Ltd, 2009:202."},{"key":"2018062923350626000_5.1.e000207.26","doi-asserted-by":"publisher","DOI":"10.2307\/2533446"},{"key":"2018062923350626000_5.1.e000207.27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"2018062923350626000_5.1.e000207.28","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2017 https:\/\/www.r-project.org\/"},{"key":"2018062923350626000_5.1.e000207.29","doi-asserted-by":"crossref","unstructured":"Schwarzer G . meta: an R package for meta-analysis: R news, 2007.","DOI":"10.32614\/CRAN.package.meta"},{"key":"2018062923350626000_5.1.e000207.30","unstructured":"Hadley W . ggplot2: elegant graphics for data analysis. New York: Springer-Verlag, 2009."},{"key":"2018062923350626000_5.1.e000207.31","doi-asserted-by":"publisher","DOI":"10.1186\/2046-4053-3-54"},{"key":"2018062923350626000_5.1.e000207.32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.dld.2017.04.012","article-title":"Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C","volume":"49","author":"Atsukawa","year":"2017","journal-title":"Dig Liver Dis"},{"key":"2018062923350626000_5.1.e000207.33","first-page":"S49","article-title":"Twelve weeks sofosbuvir ribavirin therapy for treatment experienced chronic HCV genotype 2 Chinese patients","volume":"9","author":"Chen","year":"2015","journal-title":"Hepatol Int"},{"key":"2018062923350626000_5.1.e000207.34","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/hepr.12919","article-title":"Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: analysis of a Japanese prospective cohort","volume":"47","author":"Doi","year":"2017","journal-title":"Hepatol Res"},{"key":"2018062923350626000_5.1.e000207.35","first-page":"459A","article-title":"Efficacy and safety of DAAs therapy in hepatitis C: a multicenter real-world cohort of chronic hepatitis C patients","volume":"63","author":"Ide","year":"2016","journal-title":"Hepatology"},{"key":"2018062923350626000_5.1.e000207.36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2957\/kanzo.57.561","article-title":"Real-world effectiveness of sofosbuvir plus ribavirin in Japanese patients with genotype 2 HCV infection: a Kanagawa prospective, multicenter study","volume":"57","author":"Ikeda","year":"2016","journal-title":"Kanzo"},{"key":"2018062923350626000_5.1.e000207.37","doi-asserted-by":"crossref","unstructured":"Kanda T , Nakamura M , Yasui S , et al . Treatment of real-world hcv genotype 2-infected japanese patients with sofosbuvir plus ribavirin. Biology 2017;6:E30.doi:10.3390\/biology6020030","DOI":"10.3390\/biology6020030"},{"key":"2018062923350626000_5.1.e000207.38","first-page":"S1015","article-title":"History of HCC plus IL28B genotype non-major relate to the treatment failure of sofosbuvir and ribavirin combination Therapy for GT2 chronic hepatitis C","volume":"11","author":"Karino","year":"2017","journal-title":"Hepatol Int"},{"key":"2018062923350626000_5.1.e000207.39","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/jgh.13743","article-title":"Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy","volume":"32","author":"Kozuka","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"2018062923350626000_5.1.e000207.40","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00535-016-1279-9","article-title":"ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C","volume":"52","author":"Morio","year":"2017","journal-title":"J Gastroenterol"},{"key":"2018062923350626000_5.1.e000207.41","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/hepr.12867","article-title":"ITPA gene variation and ribavirin-induced anemia in patients with genotype 2 chronic hepatitis C treated with sofosbuvir plus ribavirin","volume":"47","author":"Murakawa","year":"2017","journal-title":"Hepatol Res"},{"key":"2018062923350626000_5.1.e000207.42","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1159\/000448824","article-title":"Safety, tolerability, and efficacy of sofosbuvir plus ribavirin in elderly patients infected with hepatitis c virus genotype 2","volume":"34","author":"Nishida","year":"2016","journal-title":"Dig Dis"},{"key":"2018062923350626000_5.1.e000207.43","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.antiviral.2016.10.012","article-title":"Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis","volume":"136","author":"Ogawa","year":"2016","journal-title":"Antiviral Res"},{"key":"2018062923350626000_5.1.e000207.44","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1002\/jmv.24776","article-title":"Predictors of treatment efficacy and ALT non-normalization with sofosbuvir\/ribavirin therapy for patients with hepatitis C virus genotype 2","volume":"89","author":"Watanabe","year":"2017","journal-title":"J Med Virol"},{"key":"2018062923350626000_5.1.e000207.45","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1159\/000448823","article-title":"Efficacy and safety of sofosbuvir plus ribavirin treatment for patients with chronic hepatitis C Genotype 2","volume":"34","author":"Sugimoto","year":"2016","journal-title":"Dig Dis"},{"key":"2018062923350626000_5.1.e000207.46","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/liv.13082","article-title":"A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection","volume":"36","author":"Kao","year":"2016","journal-title":"Liver Int"},{"key":"2018062923350626000_5.1.e000207.47","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jvh.12722","article-title":"Real-world effectiveness of ombitasvir\/paritaprevir\/ritonavir\u00b1dasabuvir\u00b1ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: a meta-analysis","volume":"24","author":"Wedemeyer","year":"2017","journal-title":"J Viral Hepat"},{"key":"2018062923350626000_5.1.e000207.48","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03763.x"},{"key":"2018062923350626000_5.1.e000207.49","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/apt.13761","article-title":"Effectiveness and tolerability of simeprevir and sofosbuvir in nontransplant and post-liver transplant patients with hepatitis C genotype 1","volume":"44","author":"Lutchman","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"2018062923350626000_5.1.e000207.50","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2015-000056"},{"key":"2018062923350626000_5.1.e000207.51","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/apt.12300","article-title":"Systematic review: Asian patients with chronic hepatitis C infection","volume":"37","author":"Nguyen","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2018062923350626000_5.1.e000207.52","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated hcv infection","volume":"376","author":"Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"2018062923350626000_5.1.e000207.53","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12279"},{"key":"2018062923350626000_5.1.e000207.54","first-page":"S890","article-title":"Role of generics in treatment of hepatitis C infection","volume":"28","author":"Umar","year":"2016","journal-title":"J Ayub Med Coll Abbottabad"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2018-000207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T21:21:31Z","timestamp":1720387291000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2018-000207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,6,29]]},"published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1136\/bmjgast-2018-000207"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2018-000207","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}